Latest news

• Janssen’s single tablet Symtuza gains NHS England funding 

  Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]).is once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV-1 infection in adults and adolescents aged ... Symtuza was approved a year ago in Europe,

• Positive trial results for Janssen’s Symtuza boosts its HIV credentials

  The STR provided ‘effective’ and ‘durable’ viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

• Janssen wins European approval for Symtuza

  It’s the first complete, single-tablet regimen (STR) based on its big-selling protease inhibitor Prezista (darunavir), which it combines with cobicistat, emtricitabine and tenofovir alafenamide (TAF).

• CHMP backs three immuno-oncology drugs for solid tumours

  The once-daily product combines darunavir with cobicistat, emtricitabine and tenofovir alafenamide (TAF) and is vying to compete with therapies from GlaxoSmithKline's ViiV unit.

• Gilead plans fightback against HIV arch-rival ViiV

  its Genvoya and Stribild products - which needs to be boosted with cobicistat.